This article is more than 5 years old. Information may no longer be current.

Sirna releases phase 1 trial results for AMD drug

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

SAN FRANCISCO — Sirna-027, a new drug for treating age-related macular degeneration, appears safe in a preliminary clinical study, according to a press release by Sirna Therapeutics Inc., the drug’s developer.

Sirna-027 is an RNAi-based therapy for AMD. The results of a phase-1 trial showed all single ascending doses of the drug were safe and well tolerated by patients. At 8 weeks follow-up, visual acuity had stabilized in 26 patients (100%) treated with a single injection. Five patients (19%) also had an improvement in visual acuity (VA) of 3 lines or more, according to the release.

At 3 months follow-up, 24 of 26 patients (92%) maintained stabilized VA, four patients (15%) had a clinically significant improvement in VA, and only two patients (8%) had a reduction in VA of 3 lines or more.

Some patients also showed a decrease in foveal thickness, indicating the biological activity of Sirna-027, company officials said in the release.

Sirna is co-developing the drug with Allergan Inc. Phase-2 trials are expected during the second half of 2006, according to the release.